BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33518189)

  • 1. Postmenopausal Hyperandrogenism: Evaluation and Treatment Strategies.
    Zaman A; Rothman MS
    Endocrinol Metab Clin North Am; 2021 Mar; 50(1):97-111. PubMed ID: 33518189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.
    Hirschberg AL
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1243-1253. PubMed ID: 36409990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal hyperandrogenism.
    Yoldemir T
    Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of postmenopausal androgen excess.
    Lambrinoudaki I; Dafnios N; Kondi-Pafiti A; Triantafyllou N; Karopoulou E; Papageorgiou A; Augoulea A; Armeni E; Creatsa M; Vlahos N
    Gynecol Endocrinol; 2015 Oct; 31(10):760-4. PubMed ID: 26287476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperandrogenism after menopause.
    Markopoulos MC; Kassi E; Alexandraki KI; Mastorakos G; Kaltsas G
    Eur J Endocrinol; 2015 Feb; 172(2):R79-91. PubMed ID: 25225480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.
    Meczekalski B; Szeliga A; Maciejewska-Jeske M; Podfigurna A; Cornetti P; Bala G; Adashi EY
    Gynecol Endocrinol; 2021 Aug; 37(8):677-682. PubMed ID: 33759685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperandrogenism after menopause: Ovarian or adrenal origin?].
    Sarfati J; Moraillon-Bougerolle M; Christin-Maitre S
    Gynecol Obstet Fertil Senol; 2022 Oct; 50(10):675-681. PubMed ID: 35609786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.
    Mamoojee Y; Ganguri M; Taylor N; Quinton R
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):13-20. PubMed ID: 28980338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of postmenopausal virilization.
    Alpañés M; González-Casbas JM; Sánchez J; Pián H; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2584-8. PubMed ID: 22669303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hyperandrogenemia in postmenopausal woman as a presentation of ovarian hyperthecosis. Case report and mini review of the literature.
    Czyzyk A; Latacz J; Filipowicz D; Podfigurna A; Moszynski R; Jasinski P; Sajdak S; Gaca M; Genazzani AR; Meczekalski B
    Gynecol Endocrinol; 2017 Nov; 33(11):836-839. PubMed ID: 28604129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rare case of postmenopausal hyperandrogenism due to ovarian hyperthecosis and hilus cell hyperplasia.
    Johnson JE; Hussain M; Rathore A; Wolfe K
    Post Reprod Health; 2022 Mar; 28(1):51-55. PubMed ID: 35144514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.
    Manieri C; Di Bisceglie C; Fornengo R; Grosso T; Zumpano E; Calvo F; Berardengo E; Volante M; Papotti M
    J Endocrinol Invest; 1998 Feb; 21(2):128-32. PubMed ID: 9585388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse stromal Leydig cell hyperplasia: a unique cause of postmenopausal hyperandrogenism and virilization.
    Taylor HC; Pillay I; Setrakian S
    Mayo Clin Proc; 2000 Mar; 75(3):288-92. PubMed ID: 10725957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Thresholds for Androgen-Producing Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry.
    Sharma A; Kapoor E; Singh RJ; Chang AY; Erickson D
    Clin Chem; 2018 Nov; 64(11):1636-1645. PubMed ID: 30068692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism: A case report.
    Chen M; Zhou W; Zhang Z; Zou Y; Li C
    Medicine (Baltimore); 2018 Mar; 97(10):e0093. PubMed ID: 29517680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies.
    Yance VRV; Marcondes JAM; Rocha MP; Barcellos CRG; Dantas WS; Avila AFA; Baroni RH; Carvalho FM; Hayashida SAY; Mendonca BB; Domenice S
    Eur J Endocrinol; 2017 Jul; 177(1):93-102. PubMed ID: 28432270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sex steroids on women's health: implications for practitioners.
    Derman RJ
    Am J Med; 1995 Jan; 98(1A):137S-143S. PubMed ID: 7825634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin.
    Vollaard ES; van Beek AP; Verburg FA; Roos A; Land JA
    J Clin Endocrinol Metab; 2011 May; 96(5):1197-201. PubMed ID: 21307133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary.
    Krug E; Berga SL
    Obstet Gynecol; 2002 May; 99(5 Pt 2):893-7. PubMed ID: 11975949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulfate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature.
    Herrera JD; Davidson JA; Mestman JH
    Endocr Pract; 2009 Mar; 15(2):149-52. PubMed ID: 19289327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.